KB001 ( DrugBank: KB001 )


1 disease
IDDisease name (Link within this page)Number of trials
299Cystic fibrosis2

299. Cystic fibrosis


Clinical trials : 1,695 Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01695343
(ClinicalTrials.gov)
December 201225/9/2012Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic TreatmentA Phase 2, Randomized, Double-blind, Placebo-controlled, Repeat-dose Study of KB001-A in Subjects With Cystic Fibrosis Infected With Pseudomonas AeruginosaCystic FibrosisBiological: KB001-A;Drug: Placebo ComparatorKaloBios PharmaceuticalsNULLCompleted12 Years50 YearsBoth182Phase 2United States;Australia;Israel;New Zealand
2NCT00638365
(ClinicalTrials.gov)
March 200812/3/2008Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas AeruginosaA Phase I/II Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas AeruginosaCystic FibrosisBiological: KB001;Other: PlaceboKaloBios PharmaceuticalsNULLCompleted12 YearsN/AAll27Phase 1/Phase 2United States